Conclusion of a non-exclusive discount agreement for medicinal products containing brimonidine

Summary

The tender concerns the conclusion of non-exclusive pharmaceutical discount agreements for medicinal products containing brimonidine, excluding single-dose presentations, ATC S01EA05. DAK-Gesundheit intends to conclude agreements with as many interested pharmaceutical companies as possible. The agreements are planned to run from 1 October 2026 to 30 September 2028, with one possible 12-month extension, and will end automatically if an exclusive agreement for the active substance enters into force. Precise participation, compliance and submission requirements must be checked in the official tender documents.